Related Experiment Video

Updated: May 30, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.5K

[Molecularly defined renal cell carcinomas]

C Stöhr1,2,3, A Fiegl1,2,3, C Bercebal1,2,3

  • 1Institut für Pathologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Deutschland.

Pathologie (Heidelberg, Germany)
|January 27, 2025
PubMed
Abstract

Insights

The 2022 WHO classification introduces molecularly defined tumors, including specific types of renal cell carcinoma (RCC) based on genetic alterations. This advances tumor biology understanding and diagnostic accuracy.

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Context:

  • The World Health Organization (WHO) released its 2022 classification of urinary and male genital tumors, incorporating recent scientific advancements.
  • This revision emphasizes molecular characteristics in tumor classification.

Purpose:

  • To summarize the updated recommendations for classifying molecularly defined tumors in the 2022 WHO classification.
  • To highlight the significance of molecular alterations in tumor biology and treatment.

Summary:

  • The 2022 WHO classification introduces a new category for molecularly defined tumors.
  • This includes TFE3-rearranged Renal Cell Carcinoma (RCC), TFEB-altered RCC, ELOC-mutated RCC, FH-deficient RCC, SDH-deficient RCC, ALK-rearranged RCC, and SMARCB1-deficient RCC.
  • These classifications are based on specific genetic alterations impacting tumor biology.

Impact:

  • Facilitates the diagnosis of tumors with potentially equivocal morphologies.
  • Reflects the growing importance of molecular profiling in guiding therapeutic strategies.
  • Provides a framework for understanding tumor heterogeneity and developing targeted treatments.
Keywords:
Basic helix-loop-helix leucine zipper transcription factorsImmunohistochemistryMale genital neoplasmsReceptor protein-tyrosine kinasesWorld Health Organization

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

8.8K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.5K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
4.9K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K